Yusuke Nakamura to HLA-A24 Antigen
This is a "connection" page, showing publications Yusuke Nakamura has written about HLA-A24 Antigen.
Connection Strength
0.657
-
Multiple therapeutic peptide vaccines for patients with advanced gastric cancer. Int J Oncol. 2017 May; 50(5):1655-1662.
Score: 0.152
-
Identification of HLA-A24-restricted novel T Cell epitope peptides derived from P-cadherin and kinesin family member 20A. J Biomed Biotechnol. 2012; 2012:848042.
Score: 0.109
-
Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci. 2007 Nov; 98(11):1803-8.
Score: 0.079
-
Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette-Guerin for patients with non-muscle invasive bladder cancer. Cancer Immunol Immunother. 2018 Sep; 67(9):1371-1380.
Score: 0.041
-
Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer. Cancer Sci. 2017 Jul; 108(7):1452-1457.
Score: 0.039
-
Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. J Exp Clin Cancer Res. 2017 02 28; 36(1):36.
Score: 0.038
-
Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Cancer Sci. 2017 Jan; 108(1):73-80.
Score: 0.037
-
Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. Clin Immunol. 2016 05; 166-167:48-58.
Score: 0.035
-
Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J Oncol. 2012 Oct; 41(4):1297-304.
Score: 0.027
-
A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells. Cancer Sci. 2011 Apr; 102(4):697-705.
Score: 0.025
-
Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci. 2009 Aug; 100(8):1502-9.
Score: 0.022
-
[Phase I study of combination therapy with peptide vaccine and anti-cancer drug for colorectal cancer]. Gan To Kagaku Ryoho. 2008 Nov; 35(12):2268-70.
Score: 0.021
-
Ring finger protein 43 as a new target for cancer immunotherapy. Clin Cancer Res. 2004 Dec 15; 10(24):8577-86.
Score: 0.016
-
Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis. Clin Cancer Res. 2004 Oct 01; 10(19):6437-48.
Score: 0.016